Skip to main content
SpringerLink
Log in

Testosterone therapy in men: Clinical and pharmacological perspectives

  • Review Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

There is increasing evidence that androgen therapy in men may be effectively applied in several conditions to improve well being and health. Classical indications for androgen therapy in men may be effectively applied in several conditions to improve well being and health. Classical indications for androgen therapy in males are represented by primary or secondary hypogonadism, delayed puberty, aplastic anemia and that secondary to chronic renal failure, protein wasting diseases such as trauma, burns, tumors and infectious diseases. Androgen innovating applications in men are represented by aging and visceral obesity associated with the metabolic syndrome. In addition, it is clear that appropriate testosterone treatment can be adequately used in male contraception, provided spermatogenesis is abolished and tolerability is adequate. Due to unphysiological hormone levels achieved by currently available testosterone preparations, new delivery systems have been produced to achieve more physiological and sustained hormone levels and improve tolerability and action at the levels of target tissues. Some of them are now available in several countries and new formulas are under development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wilson J.D., Griffin J.E. The use and misuse of androgens. Metabolism 1980, 29: 1278–1295.

    CAS  PubMed  Google Scholar 

  2. Schally A.V., Arimura A., Kastin A.J. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 1971, 173: 1036–1038.

    CAS  PubMed  Google Scholar 

  3. Sharpe R.M. Regulation of spermatogenesis. In: Knobil E., Neill J.D. (Eds.), The physiology of reproduction. Raven Press, New York, 1994, vol. 1, p. 1363–1434.

    Google Scholar 

  4. Anderson R.A., Wallace E.H., Groome N.P., Bellis A.J., Wu F.C.U. Physiological relationship between inhibin B, follicle stimulating hormone secretion and spermatogenesis in normal men and response to gonadotrophin suppression by exogenous testosterone. Hum. Reprod. 1997, 12: 746–751.

    CAS  PubMed  Google Scholar 

  5. Luke M.C., Coffey D.S. The male sex accessory tissues: structure, androgen action, and physiology. In: Knobil E., Neill J.D. (2 Eds.), The physiology of reproduction. Raven Press, New York, 1994, vol. 1, p. 1435–1487.

    Google Scholar 

  6. Mooradian A.D., Morley J.E., Korenman S.G. Biological actions of androgens. Endocr. Rev. 1987, 8: 1–28.

    CAS  PubMed  Google Scholar 

  7. Bardin C.W., Swerdloff R.S., Santen R.J. Androgens: risks and beneficts. J. Clin. Endocrinol. Metab. 1991, 73: 4–7.

    CAS  PubMed  Google Scholar 

  8. Dickinson P., Zinneman H.H., Swaim W.R., Doe R.P., Seal U.S. Effects of testosterone treatment on plasma proteins and amino acids in men. J. Clin. Endocrinol. Metab. 1969, 29: 837–841.

    CAS  PubMed  Google Scholar 

  9. Solvom A. Effect of androgens on serum lipids and lipoproteins. Lipids 1980, 51: 1335–1337.

    Google Scholar 

  10. Heiss G., Tamir I., Davis C.E. Lipoprotein-cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1980, 61: 302–315.

    CAS  PubMed  Google Scholar 

  11. Kirkland R.T., Keenan B.S., Probstfield J.D., Patsch W., Lin T.L., Clayton G.W., Insull W. Decrease in plasma high-density lipoprotein cholesterol levels at puberty in boys with delayed adolescence: correlation with plasma testosterone levels. JAMA 1987, 257: 502–507.

    CAS  PubMed  Google Scholar 

  12. Sorva R., Kuusi T., Taskinen M.R., Perheentupa J., Nikkila E.A. Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 1988, 69: 191–197.

    CAS  PubMed  Google Scholar 

  13. Root A., Steinberger E., Smith K. Isosexual pseudoprecocity in a 6-year-old boy with a testicular interstitial cell adenoma. J. Pediatr. 1972, 80: 264–268.

    CAS  PubMed  Google Scholar 

  14. Santulli R., Sprando R.L., Awoniyi C.A., Ewing L.L., Zirkin B.R. To what extent can spermatogenesis be maintained in the hypophysectomized adult rat testis with exogenously administered testosterone? Endocrinology 1990, 126: 95–101.

    CAS  PubMed  Google Scholar 

  15. O’Donnel L., McLachlan R.I., Wreford N.G., De Kretser D.M., Robertson D.M. Testosterone withdrawal promotes stage-specific detachment of round spermatids from the seminiferous epithelium. Biol. Reprod. 1996, 55: 895–901.

    Google Scholar 

  16. Tesarik J., Guido M., Mendoza C., Greco E. Human spermatogenesis in vitro: respective effects of follicle-stimulating hormone and testosterone on meiosis, spermiogenesis, and Sertoli cell apoptosis. J. Clin. Endocrinol. Metab. 1998, 83: 4467–4473.

    CAS  PubMed  Google Scholar 

  17. Erkkila K., Henriksen K., Hirvonen V., Rannikko S., Salo J., Parvinen M., Dunkel L. Testosterone regulates apoptosis in adult human seminiferous tubules in vitro. J. Clin. Endocrinol. Metab. 1997, 82: 2314–2321.

    CAS  PubMed  Google Scholar 

  18. Berg J.P. Oestrogens-essentials for reproduction in males, too. Eur. J. Endocrinol. 1998, 138: 497–498.

    CAS  PubMed  Google Scholar 

  19. Forbes G.B. The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism 1985, 34: 571–573.

    CAS  PubMed  Google Scholar 

  20. Young N.R., Baker H.W.G., Liu G., Seeman E. Body composition and muscle strenght in healthy men receiving testosterone enanthate for contraception. J. Clin. Endocrinol. Metab. 1993, 77: 1028–1032.

    CAS  PubMed  Google Scholar 

  21. Ammus S.S. The role of androgens in the treatment of hematologic disorders. Adv. Intern. Med. 1989, 34: 191–208.

    CAS  PubMed  Google Scholar 

  22. Gardner F.H., Nathan D.G., Piomelli S., Cummins J.F. The erythrocythaemic effects of androgens. Br. J. Haematol. 1968, 14: 611–615.

    CAS  PubMed  Google Scholar 

  23. Bagatell C.J., Matsumoto A.M., Christenses R.B., Rivier J.E., Bremner W.J. Comparison of gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J. Clin. Endocrinol. Metab. 1993, 77: 427–432.

    CAS  PubMed  Google Scholar 

  24. Bizzarro A., Valentini G., Di Martino G., Da Ponte A., De Bellis A., Iacono G. Influence of testosterone therapy on clinical and immunological features of autoimmune diseases associated with Klinefelter’s syndrome. J. Clin. Endocrinol. Metab. 1987, 64: 32–36.

    CAS  PubMed  Google Scholar 

  25. Finkelstein J.S., Klibanski A. Effects of androgens on bone metabolism. In: Nieschlag E.B., Behre H.M. (Eds.), Testosterone: action, deficiency, substitution. Springer, Germany, 1990, p. 204–218.

    Google Scholar 

  26. Finkelstein J.S., Klibanski A., Neer R.M., Greenspan S.L., Rosenthal D.I., Crowley W.E.Jr. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann. Intern. Med. 1987, 106: 354–361.

    CAS  PubMed  Google Scholar 

  27. Jackson J.A., Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine (Baltimore) 1990, 69: 137–152.

    CAS  Google Scholar 

  28. Behre H.M., Kliesch S., Leifke E., Link T.M., Nieschlag E. Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 1997, 82: 2386–2390.

    CAS  PubMed  Google Scholar 

  29. Eriksen E.F., Colvard D.S., Berg N.J., Graham M.L., Mann K.G., Spelsberg T.C., Riggs B.L. Evidence of estrogen receptors in normal human osteoblast- like cells. Science 1988, 241: 84–86.

    CAS  PubMed  Google Scholar 

  30. Tanaka S., Haji M., Nishi Y., Yanase T., Takayanagi R., Nawata H. Aromatase activity in human osteoblast-like osteosarcoma cell. Calcif. Tissue Int. 1993, 52: 107–109.

    CAS  PubMed  Google Scholar 

  31. Carani C., Simoni M., Faustini-Fustini M., Serpente S., Boyd J., Korach K.S., Simpson E.R. Aromatase deficiency in the male: effect of testosterone and estradiol treatment. N. Engl. J. Med. 1997, 337: 91–95.

    CAS  PubMed  Google Scholar 

  32. Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., Williams T.C., Lubahn D.B., Korach K.S. Estrogen resistance caused by a mutation in the estrogen- receptor gene in a man. N. Engl. J. Med. 1994, 331: 1056–1061.

    CAS  PubMed  Google Scholar 

  33. Bagatell C.J., Heiman J.R., Rivier J.E., Bremner W.J. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J. Clin. Endocrinol. Metab. 1994, 78: 711–716.

    CAS  PubMed  Google Scholar 

  34. Davidson J.M., Kwan M., Greenleaf W.J. Hormonal replacement and sexuality in men. Clin. Endocrinol. Metab. 1982, 11: 599–623.

    CAS  PubMed  Google Scholar 

  35. Gooren L.J. Androgen levels and sex functions in testosteronetreated hypogonadal men. Arch. Sex. Behav. 1987, 16: 463–473.

    CAS  PubMed  Google Scholar 

  36. Salmimies P., Kockott G., Pirke K.M., Vogt H.J., Schill W.B. Effects of testosterone replacement on sexual behavior in hypogonadal men. Arch. Sex. Behav. 1982, 11: 345–353.

    CAS  PubMed  Google Scholar 

  37. Davidson J.M., Camargo C.A., Smith E.R. Effects of androgens on sexual behaviour in hypogonadal men. J. Clin. Endocrinol. Metab. 1979, 48: 955–958.

    CAS  PubMed  Google Scholar 

  38. Kwan M., Greenleaf W.J., Mann J., Crapo L., Davidson J.M. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J. Clin. Endocrinol. Metab. 1983, 57: 557–562.

    CAS  PubMed  Google Scholar 

  39. O’Carroll R., Shapiro C., Bancroft J. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin. Endocrinol. (Oxf.) 1985, 23: 527–538.

    Google Scholar 

  40. Skakkebaek N.E., Bancroft J., Davidson D.W., Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin. Endocrinol. (Oxf.) 1981, 14: 49–61.

    CAS  Google Scholar 

  41. Michael R.P., Zumpe D. Annual cycles of aggression and plasma testosterone in captive male rhesus monkeys. Psychoneuroendocrinology 1978, 3: 217–220.

    CAS  PubMed  Google Scholar 

  42. Su T.P., Pagliaro M., Schmidt P.J., Pickar D., Wolkowitz O., Rubinow D.R. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993, 269: 2760–2764.

    CAS  PubMed  Google Scholar 

  43. Anderson R.A., Bancroft J., Wu F.C. The effects of exogenous testosterone on sexuality and mood of normal men. J.Clin. Endocrinol. Metab. 1992, 75: 1503–1507.

    CAS  PubMed  Google Scholar 

  44. Bagatell C.J., Heiman J.R., Matsumoto A.M., Rivier J.E., Bremner W.J. Metabolic and behavioral effects of high dose, exogenous testosterone in healthy men. J. Clin. Endocrinol. Metab. 1994, 79: 561–567.

    CAS  PubMed  Google Scholar 

  45. Honrath W.L., Wolff A., Meli A. The influence of the amount of solvent (sesame oil) on the degree and duration of action of subcutaneously administered testosterone and its propionate. Steroids 1963, 2: 425–428.

    CAS  Google Scholar 

  46. James K.C., Nicholls P.J., Roberts M. Biological half-lives of 4-14C testosterone and some of its esters after injection into the rat. J. Pharm. Pharmacol. 1969, 21: 24–27.

    CAS  PubMed  Google Scholar 

  47. Snyder P.J., Lawrence D.A. Treatment of male hypogonadism with testosterone enanthate. J. Clin. Endocrinol. Metab. 1980, 51: 1335–1339.

    CAS  PubMed  Google Scholar 

  48. Sokol R.Z., Palacios A., Campfield L.A., Saul C., Swerdloff R.S. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil. Steril. 1982, 37: 425–430.

    CAS  PubMed  Google Scholar 

  49. Alkalay D., Khemani L., Wagner W.E. Sublingual and oral administration of methyltestosterone. A comparison of drug bioavailability. J. Clin. Pharmacol. 1973, 13: 142–151.

    CAS  Google Scholar 

  50. Foss G.L. A comparison of the relative efficacy of methyltestosterone by the gastric and oral transmucosal routes. J. Endocrinol. 1956, 13: 269–273.

    CAS  PubMed  Google Scholar 

  51. Mosbach E.H., Shefer S., Abell L.L. Identification of the fecal metabolites of 17 alfamethyltestosterone in the dog. J. Lipid. Res. 1968, 9: 93–97.

    CAS  PubMed  Google Scholar 

  52. Segaloff A., Gabbard R.B., Carriere B.T. The metabolism of 4-14C-17 alfa-methyltestosterone. Steroids 1965, 1 (Suppl.): 149–158.

    CAS  Google Scholar 

  53. Alkalay D., Khemani L., Bartlett M.F. Spectrophotofluorometric determination of methyltestosterone in plasma or serum. J. Pharm. Sci. 1972, 61: 1746–1749.

    CAS  PubMed  Google Scholar 

  54. Gooren L.J. A ten-year safety study of the oral androgen testosterone undecanoate. J. Androl. 1994, 15: 212–215.

    CAS  PubMed  Google Scholar 

  55. Cunningham G.R., Cordero E., Thornby J.I. Testosterone replacement with transdermal therapeutic systems. JAMA 1989, 261: 2525–2530.

    CAS  PubMed  Google Scholar 

  56. Wilson J.D., Walker J.D. The conversion of testosterone to 5a-androstane-17β- ol-3 one (dihydrotestosterone) by skin slices of man. J. Clin. Invest. 1969, 48: 371–379.

    CAS  PubMed Central  PubMed  Google Scholar 

  57. Behre H.M., Bohmeyer J., Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to agematched normal controls. Clin. Endocrinol. (Oxf.) 1994, 40: 341–349.

    CAS  Google Scholar 

  58. Meikle A.W., Arver S., Dobs A.S., Sanders S.W., Rajaram L., Mazer N.A. Pharmacokinetics and metabolism of a permeation enhanced testosterone transdermal system in hypogonadal men: influence of application site-a clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81: 1832–1840.

    CAS  PubMed  Google Scholar 

  59. Meikle A.W., Mazer N.A., Moellmer J.F., Stringham J.D., Tolman K.G., Sanders S.W., Odell W.D. Enhanced transdermal delivery of testosterone across the non scrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J. Clin. Endocrinol. Metab. 1992, 74: 623–628.

    CAS  PubMed  Google Scholar 

  60. Mazer N.A., Sanders S.W., Ebert C.D., Meikle A.W. Mimicking the circadian pattern of testosterone and metabolite levels with an enhanced transdermal delivery system. In: Gurney R., Junginger H.E., Peppas N. (Eds.), Pulsatile drug delivery: current applications and future trends. Stuttgart, Wissenshaftliche Verlagsgesellschaft mbH, 1993, p. 73–97.

    Google Scholar 

  61. Meikle A.W., Arver S., Dobs A.S., Sanders S.W., Mazer N.A. Androderm: a permeation enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism. In: Bhasin S. (Ed.), Pharmacology, biology, and clinical applications of androgens. Wiley-Liss, New York, 1996, p. 449–457.

    Google Scholar 

  62. Handelsman D.J., Conway A.J., Boyan L.M. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J. Clin. Endocrinol. Metab. 1990, 71: 216–222.

    CAS  PubMed  Google Scholar 

  63. Bhasin S., Swerdloff R.S., Steiner B., Peterson M.A., Meridores T., Galmirini M., Pandian M.R., Goldberg R., Berman N. A biodegradable testosterone microsphere formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J. Clin. Endocrinol. Metab. 1992, 74: 75–83.

    CAS  PubMed  Google Scholar 

  64. Behre H.M., Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J. Clin. Endocrinol. Metab. 1992, 75: 1204–1210.

    CAS  PubMed  Google Scholar 

  65. Behre H.M., Nieschlag E. Comparative pharmacokinetics of testosterone esters. In: Nieschlag E., Behre H.M. (Eds.), Testosterone: Action-Deficiency-Substitution. Springer, Germany, 1998, p. 329–348.

    Google Scholar 

  66. Uekama K., Otagiri M. Cyclodextrin in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 1987, 3: 1–40.

    CAS  PubMed  Google Scholar 

  67. Brewster M.E., Estes K.S., Loftsson T. Improved delivery through biological membranes. XXXI. Solubilization and stabilization of an estradiol chemical delivery system by modified b-cyclodextrin. J. Pharm. Sci. 1988, 77: 981–985.

    CAS  PubMed  Google Scholar 

  68. Stuenkel C.A., Dudley R.E., Yen S.S.C. Sublingual administration of testosterone-hydroxypropyl- beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J. Clin. Endocrinol. Metab. 1991, 72: 1054–1059.

    CAS  PubMed  Google Scholar 

  69. Partsch C.J., Weinbauer G.F., Fang R., Nieschlag E. Injectable testosterone undecanoate has more favorable pharmacokinetics and pharmacodynamics than testosterone enanthate. Eur. J. Endocrinol. 1995, 132: 514–519.

    CAS  PubMed  Google Scholar 

  70. Dobs A.S., Hoover D.R., Chen M.C., Allen R. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J. Clin. Endocrinol. Metab. 1998, 83: 33–39.

    CAS  PubMed  Google Scholar 

  71. Bagatell C.J., Bremner W.J. Androgens in men-uses and abuses. N. Engl. J. Med. 1996, 334: 707–714.

    CAS  PubMed  Google Scholar 

  72. Zgliczynski S., Ossowski M., Slowinska-Srzednicka J., Brzezinska A., Zgliczynski W., Soszynski P., Chotkowska E., Srzednicki M., Sadowski Z. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996, 121: 35–43.

    CAS  PubMed  Google Scholar 

  73. Snyder P.J. Clinical use of androgens. Annu. Rev. Med. 1984, 35: 207–217.

    CAS  PubMed  Google Scholar 

  74. Richman R.A., Kirsch L.R. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N. Engl. J. Med. 1988, 319: 1563–1567.

    CAS  PubMed  Google Scholar 

  75. Butler G.E., Sellar R.E., Walker R.F. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J. Clin. Endocrinol. Metab. 1992, 75: 37–44.

    CAS  PubMed  Google Scholar 

  76. Bourguignon J.P. Linear growth as a function of age at onset of puberty and sex steroid dosage: therapeutic implications. Endocr. Rev. 1988, 9: 467–488.

    CAS  PubMed  Google Scholar 

  77. Rissanen A., Heliovaara M., Knekt P., Reunanen A., Aromaa A., Maatila J. Risk of disability and mortality due to overweight in a Finnish population. Br. Med. J. 1990, 301: 835–837.

    CAS  Google Scholar 

  78. Wannamathaa G., Shaper A.G. Body weight and mortality in middle-aged British men. Br. Med. J. 1989, 299: 1497–1502.

    Google Scholar 

  79. Vague J. The degree of masculine differentiation of obesities. Am. J. Clin. Nutr. 1956, 4: 20–21.

    CAS  PubMed  Google Scholar 

  80. Hartz A.J., Rupley D.C., Rimm A.A. The association of girth measurement with disease in 32.856 women. Am. J. Epidemiol. 1984, 119: 71–80.

    CAS  PubMed  Google Scholar 

  81. Kissebah, Vydelingum N., Murray R. Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 1982, 54: 254–260.

    CAS  PubMed  Google Scholar 

  82. Bjorntorp P. Visceral obesity: a “Civilization Syndrome”. Obes. Res. 1993, 1: 206–222.

    CAS  PubMed  Google Scholar 

  83. Vague J. La differentiation sexuelle. Facteur determinant des formes de l’obesitè. Presse Med. 1947, 55: 339–341.

    CAS  PubMed  Google Scholar 

  84. Glass A.R., Swerdloff R.S., Bray G.A., Dahms W., Atkinson R.S. Low serum testosterone sex hormone binding globulin in massively obese men. J. Clin. Endocrinol. Metab. 1977, 45: 1211–1219.

    CAS  PubMed  Google Scholar 

  85. Pasquali R., Casimirri F., Cantobelli S., Melchionda N., Morselli-Labate A.M., Fabbri R., Capelli M., Bortoluzzi L. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991, 40: 101–104.

    CAS  PubMed  Google Scholar 

  86. Vermeulen A., Kaufman J.M., Desslijpere J.P., Thomas G. Attenuated LH pulse amplitude but normal LH pulse frequency and its relation to plasma androgens in hypogonadism of obese men. J. Clin. Endocrinol. Metab. 1993, 76: 1140–1146.

    CAS  PubMed  Google Scholar 

  87. Plymate S.R., Matej L.A., Jones R.E. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J. Clin. Endocrinol. Metab. 1988, 67: 460–464.

    CAS  PubMed  Google Scholar 

  88. Nestler J.E. Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J. Clin. Endocrinol. Metab. 1993, 76: 273–274.

    CAS  PubMed  Google Scholar 

  89. Pasquali R., Casimirri F., De Iasio R., Mesini P., Boschi S., Chierici R., Flamia R., Biscotti D., Vicennati V. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J. Clin. Endocrinol. Metab. 1995, 80: 654–658.

    CAS  PubMed  Google Scholar 

  90. Pasquali R., Casimirri F., Cantobelli S., Buratti P., Bortoluzzi L., Capelli M., Morselli Labate A.M., Barbara L. Beta-endorphin response to exogenous corticotrophin- releasing hormone in obese women with different patterns of body fat distribution. Int. J. Obes. 1993, 17: 593–596.

    CAS  Google Scholar 

  91. Pasquali R., Cantobelli S., Casimirri F., Bortoluzzi L., Boschi S., Capelli M., Melchionda N., Barbara L. The role of the opioid peptides in the development of hyperinsulinemia in obese women with abdominal body fat distribution. Metabolism 1992, 41: 763–767.

    CAS  PubMed  Google Scholar 

  92. Iranmanesh A., Lizarralde G., Veldhuis J.D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J. Clin. Endocrinol. Metab. 1991, 73: 1081–1088.

    CAS  PubMed  Google Scholar 

  93. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int. J. Obes. 1996, 20: 291–302.

    CAS  Google Scholar 

  94. De Pergola G., Xu X., Yang S., Giorgino R., Bjorntorp P. Up-regulation of androgen receptor binding in male rat fat pad adipose precursor cells exposed to testosterone: study in a whole cell assay system. J. Steroid Biochem. Mol. Biol. 1990, 37: 553–558.

    PubMed  Google Scholar 

  95. Rebuffè-Scrive M., Marin P., Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int. J. Obes. 1991, 15: 791–795.

    PubMed  Google Scholar 

  96. Xu X., De Pergola G., Bjorntorp P. Testosterone increases lipolysis and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology 1991, 128: 379–382.

    CAS  PubMed  Google Scholar 

  97. Xu X., De Pergola G., Bjorntorp P. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 1990, 126: 1229–1234.

    CAS  PubMed  Google Scholar 

  98. Marin P., Holmang S., Jonsson L., Sjostrom L., Kvist H., Holm G., Lindsted G., Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-age obese men. Int. J. Obes. 1992, 16: 991–997.

    CAS  Google Scholar 

  99. Seidell J., Bjorntorp P., Sjostrom L., Kvist H., Sannerstedt R. Visceral fat accumulation in men positively associated with insulin, glucose and C-peptide levels, but negatively with testosterone levels. Metabolism 1990, 39: 897–901.

    CAS  PubMed  Google Scholar 

  100. Barett-Connor E., Khaw K-T. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988, 78: 539–545.

    Google Scholar 

  101. Haffner S.M., Katz M.S., Stern M.P., Dunn J.F. The relationship of sex hormones to hyperinsulinemia and hyperglycemia. Metabolism 1988, 37: 683–688.

    CAS  PubMed  Google Scholar 

  102. Mårin P. Effects of androgens in men with the metabolic syndrome. The Aging Male 1998, 1: 129–136.

    Google Scholar 

  103. Vermeulen A. Androgens in the aging male. J. Clin. Endocrinol. Metab. 1991, 73: 221–224.

    CAS  PubMed  Google Scholar 

  104. Hajjar R.R., Kaiser F.E., Morley J.E. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospectives analysis. J. Clin. Endocrinol. Metab. 1997, 82: 3793–3796.

    CAS  PubMed  Google Scholar 

  105. Morley J.E., Perry H.M. III, Kaiser F.E., Kraenzle D., Jensen J., Houston K., Mattammal M., Perry H.M. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J. Am. Geriatr. Soc. 1993, 41: 149–152.

    CAS  PubMed  Google Scholar 

  106. Tenover J.S. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 1992, 75: 1092–1098.

    CAS  PubMed  Google Scholar 

  107. Sih R., Morley J.E., Kaiser F.E., Perry H.M. III, Patrick P., Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. 1997, 82: 1661–1667.

    CAS  PubMed  Google Scholar 

  108. Schiavi R.C. Androgens and sexual function in men. In: Oddens B., Vermeulen A. (Eds.), Androgens and the aging male. Parthenon Publishing Group, New York, 1996, p. 111–113.

    Google Scholar 

  109. Lugg J., Rajfer J., Gonzales-Cadavit N.F. Dihydrotestosterone is the active androgen in the maintenance of nitric-oxide mediated penile erection in the rat. Endocrinology 1995, 136: 1495–1501.

    CAS  PubMed  Google Scholar 

  110. Clopper R.R., Voorhess M.L., MacGillivray M.H., Lee P.A., Mills B. Psychosexual behavior in hypopituitary men: a controlled comparison of gonadotropin and testosterone replacement. Psychoneuroendocr. 1993, 18: 149–161.

    CAS  Google Scholar 

  111. Matsumoto A.M., Bremner W.J. Endocrine control of human spermatogenesis. J. Steroid Biochem. 1989, 33: 789–790.

    CAS  PubMed  Google Scholar 

  112. Matsumoto A.M., Karpas A.E., Paulsen C.A. Reinitiation of sperm production in gonadotropin-suppressed men by administration of follicle stimulating hormone. J. Clin. Invest. 1983, 72: 1005–1015.

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Weinbauer G.F., Gockeler E., Nieschlag E. Testosterone prevents the complete suppression of spermatogenesis in the gonadotropin-releasing hormone (GnRH) antagonist-treated non-human primate (Macaca Fascicularis). J. Clin. Endocrinol. Metab. 1988, 67: 284–290.

    CAS  PubMed  Google Scholar 

  114. Sharpe R.M., Donachie K., Cooper I. Re-evaluation of the intratesticular level of testosterone required for quantitative maintenance of spermatogenesis in the rat. J. Endocrinol. 1988, 117: 19–26.

    CAS  PubMed  Google Scholar 

  115. Weinbauer G.F., Nieschlag E. The leydig cell as a target for male contraception. In: Payne A.H., Hardy H.P., Russell L.D. (Eds.), The Leydig cell. Cache River Press, Vienna, 1996, p. 629–662.

    Google Scholar 

  116. Cummings D.E., Bremner W.J. Prospects for new hormonal male contraceptives. Clin. Endocrinol. Metab. North Am. 1994, 23: 893–922.

    CAS  Google Scholar 

  117. World Health Organization task force on methods for the regulation of male fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990, 336: 955–959.

    Google Scholar 

  118. World Health Organization task force on methods for the regulation of male fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil. Steril. 1996, 65: 821–829.

    Google Scholar 

  119. Meriggiola M.C., Bremner W.J. Progestin-androgen combination regimens for male contraception. J. Andrology 1997, 18: 240–244.

    CAS  Google Scholar 

  120. Meriggiola M.C., Marcovina S., Paulsen C.A., Bremner W.J. Testosterone enanthate at the dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int. J. Androl. 1995, 18: 237–242.

    CAS  PubMed  Google Scholar 

  121. Handelsman D.J., Conway A.J., Boyland L.M. Suppression of human spermatogenesis by testosterone implants. J. Clin. Endocrinol. Metab. 1992, 75: 1326–1332.

    CAS  PubMed  Google Scholar 

  122. Behre H.M., Bans S., Kliesch S., Keck C., Simoni M., Nieschlag E. Potential of testosterone buciclate for male contraception: endocrine differences between responders and non responders. J. Clin. Endocrinol. Metab. 1995, 80: 2394–2403.

    CAS  PubMed  Google Scholar 

  123. Bremner W.J., Bagatell C.J., Steiner R.A. Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive. J. Clin. Endocrinol. Metab. 1991, 73: 465–469.

    CAS  PubMed  Google Scholar 

  124. Bagatell C.J., Matsumoto A.M., Christensen R.B., Rivier J.E., Bremner W.J. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J. Clin. Endocrinol. Metab. 1993, 77: 427–432.

    CAS  PubMed  Google Scholar 

  125. Pavlou S.N., Brewer K., Lindner J. Combined administration of a gonadotropin releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J. Clin. Endocrinol. Metab. 1991, 73: 1360–1369.

    CAS  PubMed  Google Scholar 

  126. Tom L., Bhasin S., Salameh W. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin releasing-hormone antagonist and testosterone enanthate. J. Clin. Endocrinol. Metab. 1992, 75: 476–483.

    CAS  PubMed  Google Scholar 

  127. Meriggiola M.C., Bremner W.J., Paulsen C.A., Valdiserri A., Incorvaia L., Motra R., Pavani A., Capelli M., Flamigni C. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J. Clin. Endocrinol. Metab. 1996, 81: 3018–3023.

    CAS  PubMed  Google Scholar 

  128. Behre H.M., Böckers A., Schlingheider A., Nieschlag E. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist Cetrorelix over 8 days in normal men. Clin. Endocrinol. (Oxf.) 1994, 40: 241–248.

    CAS  Google Scholar 

  129. Weinbauer G.F., Limberger A., Behre H.M., Nieschlag E. The GnRH antagonist cetrorelix inhibits spermatogenesis in the non-human primate: effects of delayed high dose testosterone substitution. Proceedings of the 9th International Congress of Endocrinology, Nice, France, 1992, p. 419.

    Google Scholar 

  130. Büchter D., Eckardstein S.V., Eckardstein A.V., Kamischke A., Simoni M., Behre H.M., Nieschlag E. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J. Clin. Endocrinol. Metab. 1999, 84: 1244–1249.

    PubMed  Google Scholar 

  131. Neumann F. The physiological action of progesterone and pharmacological effects of progestagens. Postgrad. Med. J. 1978, 54: 11–24.

    CAS  PubMed  Google Scholar 

  132. Andersson A., Edvardsen K., Skakkebaek N.E. Expression and localization of N and E-cadherin in the human testis and epididymis. Int. J. Androl. 1994, 17: 174–180.

    CAS  PubMed  Google Scholar 

  133. Schneider B.K., Pickett C.K., Zwillich C.W., Weil J.V., Mc Dermott M.T., Santen R.J., Varano L.A., White D.P. Influence of testosterone on breathing during sleep. J. Appl. Physiol. 1986, 61: 618–623.

    CAS  PubMed  Google Scholar 

  134. Ghusn H.F., Cunningham G.R. Evaluation and treatment of androgen deficiency in males. The Endocrinologist 1991, 1: 399–400.

    Google Scholar 

  135. Alen M., Rahkila P., Marniemi J. Serum lipids in power athletes self-administering testosterone and anabolic steroids. Int. J. Sports Med. 1985, 6: 139–144.

    CAS  PubMed  Google Scholar 

  136. Friedl K.E., Hannan C.J. Jr., Jones R.E., Plymate S.R. High-density lipoprotein is not decreased if an aromatizable androgen is administered. Metabolism 1990, 39: 69–74.

    CAS  PubMed  Google Scholar 

  137. Thompson P.D., Cullinane E.M., Sady S.P., Chenevert C., Saritelli A.L., Sady M.A., Herbert P.N. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989, 261: 1165–1168.

    CAS  PubMed  Google Scholar 

  138. Zmuda J.M., Fahrenbach M.C., Younkin B.T., Bausserman L.L., Terry R.B., Catlin D.H., Thompson P.D. The effect of testosterone aromatization on highdensity lipoprotein cholesterol level and postheparin lipolytic activity. Metabolism 1993, 42: 446–450.

    CAS  PubMed  Google Scholar 

  139. Bhasin S., Bremner W.J. Emerging issues in androgen replacement therapy. J. Clin. Endocrinol. Metab. 1996, 82: 3–8.

    Google Scholar 

  140. Meikle A.W., Arver S., Dobs A.S., Adolfsson J., Sanders S.W., Middleton R.G., Stephenson R.A., Hoover D.R., Rajaram L., Mazer N.A. Prostate size in hypogonadal men treated with a non scrotal permeation-enhanced testosterone transdermal system. Urology 1997, 49: 191–196.

    CAS  PubMed  Google Scholar 

  141. Jordan W.P. Jr. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and non scrotal transdermal systems. Am. J. Contact Dermat. 1997, 8: 108–113.

    PubMed  Google Scholar 

  142. Ishak K.G., Zimmerman H.J. Hepatotoxic effects of the anabolic/androgenic steroids. Semin. Liver Dis. 1987, 7: 230–236.

    CAS  PubMed  Google Scholar 

  143. Gurakar A., Caraceni P., Fagiuoli S., Van Thiel D.H. Androgenic/anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports. J. Okla. State Med. Assoc. 1994, 87: 399–404.

    CAS  PubMed  Google Scholar 

  144. Soe K.L., Soe M., Gluud C. Liver pathology associated with the use of anabolicandrogenic steroids. Liver 1992, 12: 73–79

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Unit, Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University Alma Mater Studiorum, Via Massarenti 9, 40138, Bologna, Italy

    A. Gambineri & Renato Pasquali M.D.

Authors
  1. A. Gambineri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renato Pasquali M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gambineri, A., Pasquali, R. Testosterone therapy in men: Clinical and pharmacological perspectives. J Endocrinol Invest 23, 196–214 (2000). https://doi.org/10.1007/BF03343707

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343707

Key-words

Search

Navigation